Skip to contentpdufa.bio
Home › Decisions › RHHBY 2026-11-16

RHHBY FDA decision: Nov 16, 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED

Wilserdly (Giredestrant (+ everolimus)) was approved by the FDA on November 16, 2026 for ER+/HER2-, ESR1-mutated metastatic breast cancer.

Verified against: FDA action day November 16, 2026 (FDA oncology approval notification) · Announcement November 16, 2026 (FDA oncology approval notification) · Goal date December 18, 2026 (Genentech press release).

This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 1:24 AM ET (public commit ce46f16). Dates on this page are the FDA's and the sponsor's; this line is ours.

The FDA approved Wilserdly (giredestrant) with everolimus on November 16, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease recurred or progressed on endocrine therapy.

Run-up into the decision (T-120 → T+0)

FDA decision 11/16/26$61.39$495/27/26FDA decision 11/16/26$61.39$495/27/26
Daily close, T-120 (5/27/26) through T+0. Run-up high $61.39 on 11/9/26, low $49 on 6/3/26 (T-120 to T-1). FDA decision 11/16/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-11-16
OutcomeApproved
Drug / candidateWilserdly (giredestrant) + everolimus
IndicationER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after endocrine therapy (evERA)
CompanyRoche Holding AG (Genentech)
Market-cap tierLarge
120-day run-up (T-120→T-1)+14.6%
Decision-day move+1.1%
Move measured on2026-11-16 close, against the 2026-11-13 close
Cohort decision-day move (history)1.0% median (n=828)

The PDUFA goal date was December 18, 2026 (Genentech, February 19, 2026); the FDA approved on November 16, 32 days early, and its notice says 4 weeks ahead of the goal. Per the FDA: in evERA (ESR1-mutated population) the progression-free survival hazard ratio was 0.38; median PFS 10 versus 5.5 months. This is the evERA application; the separate lidERA (adjuvant) application has its own November 30, 2026 goal and is still pending.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: FDA oncology approval notification, November 16, 2026

FDA record of the action: the FDA approved on November 16, 2026, per FDA oncology approval notification, November 16, 2026 (FDA notice). The sponsor announced it the same day. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Questions

Was Wilserdly (giredestrant) + everolimus approved by the FDA?

Yes. The FDA approved the application for Wilserdly (giredestrant) + everolimus on November 16, 2026, per the FDA's own record. The primary source is linked on this page.

Which company is behind Wilserdly (giredestrant) + everolimus?

Wilserdly (giredestrant) + everolimus is a Roche Holding AG (Genentech) (RHHBY) program. The FDA decision came on November 16, 2026; the company's own announcement is linked on this page.

How did RHHBY stock react to the FDA decision?

RHHBY moved +1.1%, measured as the 2026-11-16 close against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.